scholarly journals The Prevalence of Depression in Iranian Women With Breast Cancer: A Meta-Analysis

2020 ◽  
Vol 26 (2) ◽  
pp. 170-181
Author(s):  
Parvaneh Isfahani ◽  
◽  
Seydeh Mahboubeh Hossieni Zare ◽  
Monireh Shamsaii ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prevalence Rate ◽  
Meta Analysis ◽  
Medical Science ◽  
Original Research ◽  
Iranian Women ◽  
Physical Conditions ◽  
Prevalence Of Depression ◽  
Emotional Effects

Aims Breast cancer is among the most prevalent cancers in women and has mental and emotional effects, leading to declined quality of life. The current this study aimed to determine the prevalence rate of depression in Iranian women with breast cancer. Methods & Materials This study was conducted using a meta-analysis method at Zabol University of Medical Science in March 2019. Six electronic databases were searched and evaluated for original research papers published on the prevalence of depression in Iranian women with breast cancer. Finally, 15 articles were selected and analysed using Comprehensive Meta-Analysis software. Findings Overall, the prevalence rate of depression in Iranian women with breast cancer was 18.5% (95% CI: 14.2%-23.7%). The highest reported prevalence of depression in Iranian women with breast cancer was 35% in Babol City, in 2013, (95% CI: 27.8%-43%); the lowest prevalence of depression in this population was measured as 3.4% in Qom City, in 2017 (95% CI:1.2%-9%). A significant correlation was observed between the prevalence rate of depression, and sample size, year, and mean age (P<0.05). Conclusion Depression affects approximately one-fifth of women with breast cancer. Therefore, it is essential for the healthcare staff to treat the physical conditions and psychological disorders associated with breast cancer.

scholarly journals Prevalence of Severe Depression in Iranian Women with Breast Cancer: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Parvaneh Isfahani ◽  
Marziye Arefy ◽  
Monire Shamsaii
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Severe Depression ◽  
Statistical Correlation ◽  
Original Research ◽  
Medical Sciences ◽  
Iranian Women ◽  
Research Papers ◽  
Emotional Effects

Background. Breast cancer is one of the most common cancers in women and has mental and emotional effects, which lead to a decline in their quality of life. This study is aimed at determining the prevalence of severe depression in Iranian women with breast cancer. Methods. This meta-analysis study was conducted at Zabol University of Medical Sciences in 2019. Seven electronic databases were searched and evaluated for original research papers published on the prevalence of severe depression in Iranian women with breast cancer. Finally, 13 articles were selected and analyzed via Comprehensive Meta-Analysis software. Results. Overall, the prevalence of severe depression in Iranian women with breast cancer was 11% (95% CI (7.2, 16.5)). The highest prevalence was 44% in Tehran City in 2015 (95% CI (31, 57.9)), and the lowest prevalence was 0.8% in Qom City in 2017 (95% CI (0.01, 6.2)). A significant statistical correlation was observed between the prevalence of severe depression and sample size (p<0.05). Conclusion. According to the results of this study, the prevalence of severe depression affects more than one-tenth of women with breast cancer.

scholarly journals Prevalence of Depression Among Iranian Women with Breast Cancer: A Systematic Review and Meta-Analysis

Health Scope ◽  
2019 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Abbas Rezaianzadeh ◽  
Masoume Mousave ◽  
Soheil Hassanipour ◽  
Ahmad Maghsoudi ◽  
Alimohammad Mokhtari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Iranian Women ◽  
Prevalence Of Depression

scholarly journals Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis

2017 ◽  
Vol 8 (11) ◽  
pp. 337-347 ◽  
Author(s):  
Kyrillus S. Shohdy ◽  
Shaimaa Lasheen ◽  
Loay Kassem ◽  
Omar Abdel-Rahman
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Safety Profile ◽  
Meta Analysis ◽  
Metastatic Breast ◽  
High Grade ◽  
Cyclin Dependent Kinase ◽  
Breast Cancer Patients ◽  
Randomized Phase Ii

Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. Methods: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects. Results: Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12–1.93, p = 0.005], vomiting was 1.74 (95% CI: 1.09–2.76, p = 0.02), decreased appetite was 1.42 (95% CI: 1.07–1.88, p = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19–1.74, p = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29–4.13, p = 0.89), vomiting was 1.38 (95% CI: 0.25–7.75, p = 0.72), decreased appetite was 4.00 (95% CI: 0.87–18.37, p = 0.07), and high-grade diarrhea was 1.19 (95% CI: 0.44–3.21, p = 0.73). Conclusion: Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy.

scholarly journals Symptom Experience and Quality of Life of Patients with Breast Cancer Receiving Chemotherapy in Bangladesh

2016 ◽  
Vol 15 (2) ◽  
pp. 201-206
Author(s):  
Mosammat Shamsun Naher Begum ◽  
Wongchan Petpichetchian ◽  
Luppana Kitrungrote
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Medical Science ◽  
Well Being ◽  
Significant Negative Correlation ◽  
Moderate Level ◽  
Self Report ◽  
Symptom Experience ◽  
Breast Cancer Patients

Background: The present study was aimed to the relationships between symptom severity and distress and quality of life (QoL) of patients receiving chemotherapy for breast cancer.Objectives and methodology: A total number of 132 patients, attending both In-patient and Out-patient department and fulfilling the recruitment criteria were included in the study. A self-report questionnaire was used to collect data from the eligible participants by the primary investigator. The data were analyzed by using descriptive and inferential statistical tools. Results: On average, the participants of the study experienced seventeen symptoms with moderate level. The level of QoL of the participants was at moderate level (M=2.02, SD=0.39). Among all the subscales, the physical well-being had the lowest score and social well-being had highest score. Symptom experience and quality of life showed significant negative correlation. Conclusion: The patients with breast cancer would experience high symptoms during a 7-day period after receiving chemotherapy of the previous cycle. Nurses need to perform full measurement of multiple symptoms when care for breast cancer patients after the administration of chemotherapy.Bangladesh Journal of Medical Science Vol.15(2) 2016 p.201-206

scholarly journals The impact of lifestyle interventions on therapy associated side effects in postmenopausal breast cancer survivors: systematic reviews and meta-analysis

2019 ◽  
Author(s):  
Jean Paul Muambngu Milambo ◽  
Maritha Kotze ◽  
John Akudugu
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Breast Cancer Survivors ◽  
Meta Analysis ◽  
Postmenopausal Breast Cancer ◽  
Controlled Trials ◽  
Lifestyle Interventions ◽  
Breast Cancer Patients ◽  
Related Quality

Abstract Background: Medically Supervised Exercise (MSE) are advisable for the prevention and treatment related side effects among breast cancer survivors. Aerobic and resistance either exercise, separately or in combination, have been shown to improve physical functioning and manage some symptoms in breast cancer patients. However, the level of evidence on the effects of lifestyle interventions on therapy related adverse events and the required dose responses of exercises are not yet systematically reviewed. This review was conducted to assess the efficacy of medically supervised exercises(MSE) coupled with diet in preventing/managing aromatase inhibitors induced adverse events and improving range of motion(ROM) and heath related quality of life (HRQOL) in postmenopausal breast cancer patients following treatment. Methods: Two independent authors extracted data using PRISMA guidelines of published clinical trials. We searched the Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, EMBASE, as well as clinical practice guidelines. We included only randomized controlled trials that examined exercise interventions coupled with diet interventions in postmenopausal breast cancer women. Health related quality of life (HRQOL) and range of motion were assessed as the main outcomes. Results: Random effects meta-analysis was conducted for pooling of the effect size. The age of patients varied from 50 to 60 years. The results illustrate that the mean difference (MD) in improving ROM in the MSE group versus no supervised exercises was 1.35% (95% CI: 0.63 to 2.07%, P = 0.0002; heterogeneity: Tau² = 0.71; Chi² = 112.14, df = 5 (P < 0.00001); I² = 96%). A summary of the data shows that supervised exercises significantly improved ROM and HRQOL in postmenopausal BCS on endocrine therapy compared to no supervised exercises 3.02 (95% CI: 2.59 to 3.45, P < 0.00001). These outcomes show that lifestyle interventions (MSE +diet) have positive effects on AI-associated adverse events and likely improve ROM and HRQOL in postmenopausal BC patients. Conclusion: The evidence was based on a body of research with moderate study quality. Moreover, further studies are recommended to assess the effect of lifestyle interventions on markers of inflammation as the predictors of treatment non-response and associated comorbidities.

scholarly journals Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis

2013 ◽  
Vol 202 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Luis Ayerbe ◽  
Salma Ayis ◽  
Charles D. A. Wolfe ◽  
Anthony G. Rudd
Keyword(s):  
Quality Of Life ◽  
Natural History ◽  
Meta Analysis ◽  
Potential Outcomes ◽  
Stroke Severity ◽  
Prevalence Of Depression ◽  
Rate Of Recovery ◽  
Negative Health Outcomes ◽  
Predictors Of Depression

BackgroundDepression after stroke is a distressing problem that may be associated with other negative health outcomes.AimsTo estimate the natural history, predictors and outcomes of depression after stroke.MethodStudies published up to 31 August 2011 were searched and reviewed according to accepted criteria.ResultsOut of 13 558 references initially found, 50 studies were included. Prevalence of depression was 29% (95% CI 25-32), and remains stable up to 10 years after stroke, with acumulative incidence of 39-52% within 5 years of stroke. The rate of recovery from depression among patients depressed a few months after stroke ranged from 15 to 57% 1 year after stroke. Major predictors of depression are disability, depression pre-stroke, cognitive impairment, stroke severity and anxiety. Lower quality of life, mortality and disability are independent outcomes of depression after stroke.ConclusionInterventions for depression and its potential outcomes are required.

Sign in / Sign up

Export Citation Format

Share Document